These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27773522)

  • 1. Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.
    Tamulaitis G; Venclovas Č; Siksnys V
    Trends Microbiol; 2017 Jan; 25(1):49-61. PubMed ID: 27773522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.
    Wakefield N; Rajan R; Sontheimer EJ
    FEBS Lett; 2015 Oct; 589(20 Pt B):3197-204. PubMed ID: 26364721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.
    Jia N; Mo CY; Wang C; Eng ET; Marraffini LA; Patel DJ
    Mol Cell; 2019 Jan; 73(2):264-277.e5. PubMed ID: 30503773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.
    Wang L; Mo CY; Wasserman MR; Rostøl JT; Marraffini LA; Liu S
    Mol Cell; 2019 Jan; 73(2):278-290.e4. PubMed ID: 30503774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.
    Samai P; Pyenson N; Jiang W; Goldberg GW; Hatoum-Aslan A; Marraffini LA
    Cell; 2015 May; 161(5):1164-1174. PubMed ID: 25959775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cmr1 enables efficient RNA and DNA interference of a III-B CRISPR-Cas system by binding to target RNA and crRNA.
    Li Y; Zhang Y; Lin J; Pan S; Han W; Peng N; Liang YX; She Q
    Nucleic Acids Res; 2017 Nov; 45(19):11305-11314. PubMed ID: 28977458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases.
    Walker FC; Chou-Zheng L; Dunkle JA; Hatoum-Aslan A
    Nucleic Acids Res; 2017 Feb; 45(4):2112-2123. PubMed ID: 28204542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble.
    Liu TY; Liu JJ; Aditham AJ; Nogales E; Doudna JA
    Nat Commun; 2019 Jul; 10(1):3001. PubMed ID: 31278272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of an active type III-A CRISPR effector complex.
    Smith EM; Ferrell S; Tokars VL; Mondragón A
    Structure; 2022 Aug; 30(8):1109-1128.e6. PubMed ID: 35714601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition.
    Westra ER; Semenova E; Datsenko KA; Jackson RN; Wiedenheft B; Severinov K; Brouns SJ
    PLoS Genet; 2013; 9(9):e1003742. PubMed ID: 24039596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cmr complex: an RNA-guided endoribonuclease.
    Bailey S
    Biochem Soc Trans; 2013 Dec; 41(6):1464-7. PubMed ID: 24256238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex.
    Estrella MA; Kuo FT; Bailey S
    Genes Dev; 2016 Feb; 30(4):460-70. PubMed ID: 26848046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.
    Elmore JR; Sheppard NF; Ramia N; Deighan T; Li H; Terns RM; Terns MP
    Genes Dev; 2016 Feb; 30(4):447-59. PubMed ID: 26848045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structures and mechanisms of CRISPR RNA-guided effector nucleases.
    Nishimasu H; Nureki O
    Curr Opin Struct Biol; 2017 Apr; 43():68-78. PubMed ID: 27912110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.
    Goldberg GW; Jiang W; Bikard D; Marraffini LA
    Nature; 2014 Oct; 514(7524):633-7. PubMed ID: 25174707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the Csm3-Csm4 subcomplex in the type III-A CRISPR-Cas interference complex.
    Numata T; Inanaga H; Sato C; Osawa T
    J Mol Biol; 2015 Jan; 427(2):259-73. PubMed ID: 25451598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.